NCT04085029Recruiting

Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Duke University

Start Date

9/26/2019

Completion Date

9/1/2029

Summary

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Age ≥ 18 years of age * Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment * Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s) * Patient must sign study-specific informed consent Exclusion Criteria: • None

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

OligometastasisMetastatic Cancer

Locations

Duke Cancer Institute Cary

Cary, North Carolina 27518

United States

Durham Veterans Administration Health Care System (DVAHCS)

Durham, North Carolina 27705

United States

Duke University Medical Center

Durham, North Carolina 27710

United States

Duke Women's Cancer Care Raleigh

Raleigh, North Carolina 27607

United States

Duke Raleigh Hospital

Raleigh, North Carolina 27609

United States